IP Library Granted Patent US 12,403,324
Granted Patent B2
US 12,403,324 · App. 17/682,245 · Granted Sep 2, 2025

Wearable medical device (WMD) implementing adaptive techniques to save power

Inventors: David P. Finch (Bothell, WA); Erick M. Roane (Bellevue, WA); Kenneth F. Cowan (Kirkland, WA); Derek J. Valleroy (Seattle, WA); Gregory T. Kavounas (Bellevue, WA)
Assignee: West Affum Holdings DAC
A61N1/3987A61B5/024A61B5/282A61B5/308A61B5/364A61N1/0484A61N1/3993
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,403,324
App. No.
17/682,245
Granted
Sep 2, 2025
Kind
B2
Abstract

A wearable cardioverter defibrillator (WCD) comprises a plurality of electrocardiography (ECG) electrodes and a plurality of defibrillator electrodes to contact the patient's skin when the WCD is delivering therapy to the patient, a preamplifier coupled to the ECG electrodes to obtain ECG data from the patient. a processor to receive the ECG data from the preamplifier, and a high voltage subsystem to provide a defibrillation voltage to the patient through the plurality of defibrillator electrodes in response to a shock signal received from the processor. In a first power mode of a range of power modes the preamplifier is configured to perform low-fidelity ECG acquisition and the processor is configured to perform simple arrythmia detection analysis, and in a second mode of the range of power modes the preamplifier is configured to perform high-fidelity ECG acquisition and the processor is configured to perform complex arrythmia detection analysis.

Claims (44)

1. A wearable medical device to monitor a heart rhythm of a patient, comprising:

a support structure to be worn by the patient;

a plurality of electrocardiography (ECG) electrodes coupled to the support structure and arranged to contact the patient's skin when the patient is wearing the support structure; and

a processor configured with:

a first mode to perform a first arrhythmia detection analysis using ECG data of one or more ECG channels derived from output signals of the plurality of ECG electrodes; and

a second mode to perform a second arrhythmia detection analysis using ECG data of two or more ECG channels derived from output signals of the plurality of ECG electrodes;

wherein performing the first arrhythmia detection analysis dissipates less power than performing the second arrhythmia detection analysis; and

wherein the ECG data is sensed at a lower fidelity in the first mode, and the ECG data is sensed at a higher fidelity in the second mode, wherein the lower fidelity comprises using fewer of the ECG channels, a lower gain level, and a lower data rate for continuous ECG analysis, and the higher fidelity comprises using more of the ECG channels, a higher gain level, and a higher data rate for complex ECG analysis.

2. The wearable medical device of claim 1 , wherein the processor comprises a plurality of processing devices.

3. The wearable medical device of claim 1 , wherein the first arrhythmia detection analysis is used by the processor to determine whether the ECG data is indicative of a possible arrhythmia.

4. The wearable medical device of claim 3 , wherein the processor is configured to perform the second arrhythmia detection analysis responsive to a determination that the ECG data is indicative of the possible arrhythmia.

5. The wearable medical device of claim 4 , wherein the second arrhythmia detection analysis comprises determining whether the ECG data is indicative of a shockable event.

6. The wearable medical device of claim 1 , wherein:

the first arrhythmia detection analysis comprises determining one or more patient physiological parameters using the ECG data and the second arrhythmia detection analysis determines one or more patient physiological parameters using the ECG data; and

a number of patient physiological parameters of the first arrhythmia detection analysis is less than a number of patient physiological parameters of the second arrhythmia detection analysis.

7. The wearable medical device of claim 6 , wherein:

the first arrhythmia detection analysis comprises determining the patient's heart rate; and

the second arrhythmia detection analysis comprises determining the patient's heart rate and another physiological parameter using the ECG data.

8. The wearable medical device of claim 7 , wherein:

the first arrhythmia detection analysis comprises determining the patient's heart rate using a single ECG channel of the ECG data; and

the second arrhythmia detection analysis comprises determining the patient's heart rate and QRS width using two or more ECG channels of the ECG data.

9. The wearable medical device of claim 1 , wherein the processor comprises a preamplifier circuit coupled to the plurality of ECG electrodes.

10. The wearable medical device of claim 1 , wherein the wearable medical device comprises a wearable cardioverter defibrillator.

11. A method to monitor a heart rhythm of a patient using a wearable medical device, the method comprising:

receiving, by the wearable medical device, electrocardiogram (ECG) data of a plurality of ECG channels derived from output signals of a plurality of ECG electrodes coupled to the patient;

performing, by the wearable medical device, a first arrhythmia detection analysis using the ECG data; and

performing, by the wearable medical device, a second arrhythmia detection analysis using the ECG data;

wherein the wearable medical device dissipates less power performing the first arrhythmia detection analysis than performing the second arrhythmia detection analysis; and

wherein the ECG data is sensed at a lower fidelity for the first arrhythmia detection analysis, and the ECG data is sensed at a higher fidelity for the second arrhythmia detection analysis, wherein the lower fidelity comprises using fewer of the ECG channels, a lower gain level, and a lower data rate for continuous ECG analysis, and the higher fidelity comprises using more of the ECG channels, a higher gain level, and a higher data rate for complex ECG analysis.

12. The method of claim 11 , wherein the first arrhythmia detection analysis is used to determine whether the ECG data is indicative of a possible arrhythmia.

13. The method of claim 12 , further comprising performing the second arrhythmia detection analysis responsive to a determination that the ECG data is indicative of the possible arrhythmia.

14. The method of claim 11 , wherein the second arrhythmia detection analysis comprises determining whether the ECG data is indicative of a shockable event.

15. The method of claim 14 , further comprising initiating therapy in response to a determination that the ECG data is indicative of the shockable event.

16. The method of claim 11 , wherein:

the first arrhythmia detection analysis comprises determining one or more patient physiological parameters using the ECG data and the second arrhythmia detection analysis determines one or more patient physiological parameters using the ECG data; and

a number of patient physiological parameters of the first arrhythmia detection analysis is less than a number of patient physiological parameters of the second arrhythmia detection analysis.

17. The method of claim 16 , wherein:

the first arrhythmia detection analysis comprises determining the patient's heart rate; and

the second arrhythmia detection analysis comprises determining the patient's heart rate and another physiological parameter using the ECG data.

18. The method of claim 17 , wherein:

the first arrhythmia detection analysis comprises determining the patient's heart rate using a single ECG channel of the ECG data; and

the second arrhythmia detection analysis comprises determining the patient's heart rate and QRS width using two or more ECG channels of the ECG data.

19. The method of claim 11 , wherein one ECG channel is used in the first arrhythmia detection analysis and four ECG channels are used in the second arrhythmia detection analysis.

20. The method of claim 11 , wherein the wearable medical device comprises a wearable cardioverter defibrillator.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2025
From: COWAN, KENNETH F.
To: PHYSIO-CONTROL DEVELOPMENT CO., LLC
Reel/Frame 070501/0882 →
SECURITY AGREEMENT Recorded Oct 4, 2023
From: WEST AFFUM HOLDINGS DESIGNATED ACTIVITY COMPANY
To: PERCEPTIVE CREDIT HOLDINGS IV, LP
Reel/Frame 065116/0049 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2022
From: FINCH, DAVID P.; ROANE, ERICK M.; VALLEROY, DEREK J.
To: PHYSIO-CONTROL DEVELOPMENT CO., LLC
Reel/Frame 062060/0111 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2022
From: KAVOUNAS, GREGORY T.
To: WEST AFFUM HOLDINGS CORP.
Reel/Frame 062060/0183 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2022
From: PHYSIO-CONTROL DEVELOPMENT CO., LLC
To: WEST AFFUM HOLDINGS CORP.
Reel/Frame 062060/0301 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2022
From: WEST AFFUM HOLDINGS CORP.
To: WEST AFFUM HOLDINGS DAC
Reel/Frame 060389/0694 →
Continuity (2)
Continuation 16453488 · Jun 26, 2019
Related Publication 20220296909A1 · Sep 22, 2022
References Cited (106)
US 3724455A · Unger · 1973 [cited by applicant]
US 4583524A · Hutchins · 1986 [cited by applicant]
US 4619265A · Morgan et al. · 1986 [cited by applicant]
US 4928690A · Heilman et al. · 1990 [cited by applicant]
US 4955381A · Way et al. · 1990 [cited by applicant]
US 5078134A · Heilman et al. · 1992 [cited by applicant]
US 5228449A · Christ et al. · 1993 [cited by applicant]
US 5348008A · Bornn et al. · 1994 [cited by applicant]
US 5353793A · Bornn · 1994 [cited by applicant]
US RE34800E · Hutchins · 1994 [cited by applicant]
US 5394892A · Kenny et al. · 1995 [cited by applicant]
US 5405362A · Kramer et al. · 1995 [cited by applicant]
US 5474574A · Payne et al. · 1995 [cited by applicant]
US 5662690A · Cole et al. · 1997 [cited by applicant]
US 5782878A · Morgan et al. · 1998 [cited by applicant]
US 5792204A · Snell · 1998 [cited by applicant]
US 5902249A · Lyster · 1999 [cited by applicant]
US 5913685A · Hutchins · 1999 [cited by applicant]
US 5944669A · Kaib · 1999 [cited by applicant]
US 6047203A · Sackner et al. · 2000 [cited by applicant]
US 6065154A · Hulings et al. · 2000 [cited by applicant]
US 6108197A · Janik · 2000 [cited by applicant]
US 6148233A · Owen et al. · 2000 [cited by applicant]
US 6201992B1 · Freeman · 2001 [cited by applicant]
US 6263238B1 · Brewer et al. · 2001 [cited by applicant]
US 6287328B1 · Snyder et al. · 2001 [cited by applicant]
US 6304780B1 · Owen et al. · 2001 [cited by applicant]
US 6319011B1 · Motti et al. · 2001 [cited by applicant]
US 6334070B1 · Nova et al. · 2001 [cited by applicant]
US 6356785B1 · Snyder et al. · 2002 [cited by applicant]
US 6427083B1 · Owen et al. · 2002 [cited by applicant]
US 6529875B1 · Nakajima et al. · 2003 [cited by applicant]
US 6546285B1 · Owen et al. · 2003 [cited by applicant]
US 6671545B2 · Fincke · 2003 [cited by applicant]
US 6681003B2 · Linder et al. · 2004 [cited by applicant]
US 6762917B1 · Verbiest et al. · 2004 [cited by applicant]
US 7065401B2 · Worden · 2006 [cited by applicant]
US 7559902B2 · Ting et al. · 2009 [cited by applicant]
US 7865238B2 · Brink · 2011 [cited by applicant]
US 7870761B2 · Valentine et al. · 2011 [cited by applicant]
US 7974689B2 · Volpe et al. · 2011 [cited by applicant]
US 8135462B2 · Owen et al. · 2012 [cited by applicant]
US 8140154B2 · Donnelly et al. · 2012 [cited by applicant]
US 8369944B2 · Macho et al. · 2013 [cited by applicant]
US 8548557B2 · Garstka et al. · 2013 [cited by applicant]
US 8615295B2 · Savage et al. · 2013 [cited by applicant]
US 8644925B2 · Volpe et al. · 2014 [cited by applicant]
US 8897860B2 · Volpe et al. · 2014 [cited by applicant]
US 8904213B2 · Chan et al. · 2014 [cited by applicant]
US 8904214B2 · Volpe et al. · 2014 [cited by applicant]
US 8965500B2 · Macho et al. · 2015 [cited by applicant]
US 9008801B2 · Kaib et al. · 2015 [cited by applicant]
US 9089685B2 · Sullivan et al. · 2015 [cited by applicant]
US 9131901B2 · Volpe et al. · 2015 [cited by applicant]
US 9132267B2 · Kaib · 2015 [cited by applicant]
US 9408548B2 · Volpe et al. · 2016 [cited by applicant]
US 9454219B2 · Volpe et al. · 2016 [cited by applicant]
US 9592403B2 · Sullivan · 2017 [cited by applicant]
US 20030158593A1 · Heilman et al. · 2003 [cited by applicant]
US 20050107833A1 · Freeman et al. · 2005 [cited by applicant]
US 20050107834A1 · Freeman et al. · 2005 [cited by applicant]
US 20080312709A1 · Volpe et al. · 2008 [cited by applicant]
US 20090005827A1 · Weintraub et al. · 2009 [cited by applicant]
US 20100007413A1 · Herleikson et al. · 2010 [cited by applicant]
US 20100298899A1 · Donnelly et al. · 2010 [cited by applicant]
US 20110022105A9 · Owen et al. · 2011 [cited by applicant]
US 20110288604A1 · Kaib et al. · 2011 [cited by applicant]
US 20110288605A1 · Kaib et al. · 2011 [cited by applicant]
US 20120112903A1 · Kaib et al. · 2012 [cited by applicant]
US 20120144551A1 · Guldalian · 2012 [cited by applicant]
US 20120150008A1 · Kaib et al. · 2012 [cited by applicant]
US 20120158075A1 · Kaib et al. · 2012 [cited by applicant]
US 20120265265A1 · Razavi et al. · 2012 [cited by applicant]
US 20120283794A1 · Kaib et al. · 2012 [cited by applicant]
US 20120293323A1 · Kaib et al. · 2012 [cited by applicant]
US 20120302860A1 · Volpe et al. · 2012 [cited by applicant]
US 20120310315A1 · Savage et al. · 2012 [cited by applicant]
US 20130085538A1 · Volpe et al. · 2013 [cited by applicant]
US 20130231711A1 · Kaib · 2013 [cited by applicant]
US 20130245388A1 · Rafferty et al. · 2013 [cited by applicant]
US 20130274565A1 · Langer et al. · 2013 [cited by applicant]
US 20130317852A1 · Worrell et al. · 2013 [cited by applicant]
US 20130325078A1 · Whiting et al. · 2013 [cited by applicant]
US 20140025131A1 · Sullivan et al. · 2014 [cited by applicant]
US 20140070957A1 · Longinotti-Buitoni et al. · 2014 [cited by applicant]
US 20140163663A1 · Poddar et al. · 2014 [cited by applicant]
US 20140324112A1 · Macho et al. · 2014 [cited by applicant]
US 20140378812A1 · Saroka et al. · 2014 [cited by applicant]
US 20150039053A1 · Kaib et al. · 2015 [cited by applicant]
US 20150305642A1 · Reinke et al. · 2015 [cited by applicant]
US 20150328472A1 · Sullivan et al. · 2015 [cited by applicant]
US 20160004831A1 · Carlson et al. · 2016 [cited by applicant]
US 20160029905A1 · Kovacs · 2016 [cited by examiner]
US 20160082277A1 · Foshee, Jr. et al. · 2016 [cited by applicant]
US 20160253471A1 · Volpe · 2016 [cited by examiner]
US 20160296114A1 · Finch · 2016 [cited by examiner]
US 20170003356A1 · Kaib · 2017 [cited by examiner]
US 20170156617A1 · Allavatam · 2017 [cited by examiner]
US 20180272145A1 · Medema et al. · 2018 [cited by applicant]
WO 9839061A2 · 1998 [cited by applicant]
Heartstart MRx and XL AED Algorithm—Application Note, Jul. 2001, Edition 2 Philips Healthcare, USA. [cited by applicant]
Klein, H. U., Goldenberg I., & Moss, A. J., Risk Stratification for Implantable Cardioverter Defibrillator Therapy: The Role of the Wearable Cardioverter-Defibrillator, Clinical update, European Heart Journal, May 31, 2… [cited by applicant]
Lifecor LifeVest System Model WCD 3100 Operator's Manual, 2006, PN 20B0040 Rev FI, Zoll Lifecor Corporation, Pittsburgh, PA. [cited by applicant]
LifeVest Model 4000 Patient Manual, Zoll, 2009, PN 20B0047 Rev B. [cited by applicant]
Pagan-Carlo, et al., “Encircling Overlapping Multipulse Shock Waveforms for Transthoracic Defibrillation,” JACC Journals, Dec. 1998, vol. 32 Issue 7, p. 2065-2071. [cited by applicant]
The LifeVest Network/Patient Data Management System, Zoll, 2015, 2000503 Rev A. [cited by applicant]